Intravitreal bevacizumab for posterior capsule neovascularization

Mansour Al-Mohaimeed; Saeed Al-Gehedan; Hassan Al Dhibi

doi:10.1016/j.sjopt.2010.02.002

Intravitreal bevacizumab for posterior capsule neovascularization

Saudi J Ophthalmol. 2010 Apr;24(2):63-5. doi: 10.1016/j.sjopt.2010.02.002. Epub 2010 Apr 2.

Authors

Mansour Al-Mohaimeed¹, Saeed Al-Gehedan, Hassan Al Dhibi

Affiliation

¹ College of Medicine, Al-Qassim University, Al-Qassim, P.O. Box 6655, Buraidah 51452, Saudi Arabia.

Abstract

We report a case of rapid regression of extensive posterior capsule neovascularization in a 67-year-old diabetic male patient, who developed posterior capsule opacity with neovascularization one year post cataract surgery, after a single injection of intravitreal bevacizumab (Avastin) followed by neodymium:YAG capsulotomy. Rapid regression of the posterior capsule neovascularization, and visual improvement was observed 9 days after the intervention. Posterior capsulotomy was performed successfully without bleeding. Prior to posterior capsulotomy, intravitreal bevacizumab can result in rapid and dramatic regression of posterior capsule neovascularization.

Keywords: Anti-vascular endothelial growth factor (VEGF); Bevacizumab; Posterior capsule neovascularization.